Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma
NCT ID: NCT04937387
Last Updated: 2025-08-11
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
359 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-29
Study Completion Date
2024-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTA® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Asthma
RECRUITING
PHASE3
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
NCT02924688
Asthma
COMPLETED
PHASE3
Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma
NCT03376932
Asthma
WITHDRAWN
PHASE3
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma
NCT03248128
Asthma
COMPLETED
PHASE3
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT01706198
Asthma
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Asthma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler
Group Type
EXPERIMENTAL
FF/VI
Intervention Type
DRUG
FF/VI will be administered.
ELLIPTA
Intervention Type
DEVICE
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler
Group Type
EXPERIMENTAL
FF/UMEC/VI
Intervention Type
DRUG
FF/UMEC/VI will be administered.
ELLIPTA
Intervention Type
DEVICE
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler
Group Type
EXPERIMENTAL
FF/VI
Intervention Type
DRUG
FF/VI will be administered.
ELLIPTA
Intervention Type
DEVICE
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler
Group Type
EXPERIMENTAL
FF/UMEC/VI
Intervention Type
DRUG
FF/UMEC/VI will be administered.
ELLIPTA
Intervention Type
DEVICE
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FF/VI
FF/VI will be administered.
Intervention Type
DRUG
FF/UMEC/VI
FF/UMEC/VI will be administered.
Intervention Type
DRUG
ELLIPTA
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must be 18 years or older at the time of signing the informed consent.
* Documented history asthma diagnosis as defined by the Global Initiative for Asthma (GINA) at least one year prior to Visit 0.
* Participants with inadequately controlled asthma (ACQ-6 score \>=1.5) despite Inhaled Corticosteroids/Long-Acting Beta-2-Agonists (ICS/LABA) maintenance therapy at Visit 1.
* Participants who require daily ICS/LABA for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total dose of ICS of greater than \[\>\]250 micrograms (mcg) per day fluticasone propionate \[FP, or equivalent\]).
* A best pre-bronchodilator morning (AM) FEV1 \>=30 percent (%) and less than (\<) 85% of the predicted normal value at Visit 1. Predicted values will be based upon the European Respiratory Society (ERS) Global Lung Function Initiative.
* Airway reversibility defined as \>=12% and \>=200 milliliters (mL) increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at Visit 1.
* All participants must be able to replace their current Short-Acting Beta-2-Agonists (SABA) inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed for the duration of the study. Participants must be judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.
* Male or female participants following contraceptive/barrier requirements and it should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) or a woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the study.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Participants with inadequately controlled asthma (ACQ-6 score \>=1.5) at Visit 2.
* A best pre-bronchodilator morning (AM) FEV1 \>=30% and \<90% of the predicted normal value at Visit 2. Predicted values will be based upon the ERS Global Lung Function Initiative (Quanjer).
* Liver function tests at Visit 1:
1. Alanine aminotransferase (ALT) \<2 times upper limit of normal (ULN).
2. Alkaline phosphatase \<=1.5 times ULN.
3. Bilirubin \<=1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Compliance with completion of the Electronic diary reporting defined as completion of all questions/assessment on \>=4 of the last 7 days during the run-in period.
* Documented history asthma diagnosis as defined by the Global Initiative for Asthma (GINA) at least one year prior to Visit 0.
* Participants with inadequately controlled asthma (ACQ-6 score \>=1.5) despite Inhaled Corticosteroids/Long-Acting Beta-2-Agonists (ICS/LABA) maintenance therapy at Visit 1.
* Participants who require daily ICS/LABA for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total dose of ICS of greater than \[\>\]250 micrograms (mcg) per day fluticasone propionate \[FP, or equivalent\]).
* A best pre-bronchodilator morning (AM) FEV1 \>=30 percent (%) and less than (\<) 85% of the predicted normal value at Visit 1. Predicted values will be based upon the European Respiratory Society (ERS) Global Lung Function Initiative.
* Airway reversibility defined as \>=12% and \>=200 milliliters (mL) increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at Visit 1.
* All participants must be able to replace their current Short-Acting Beta-2-Agonists (SABA) inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed for the duration of the study. Participants must be judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.
* Male or female participants following contraceptive/barrier requirements and it should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) or a woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the study.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Participants with inadequately controlled asthma (ACQ-6 score \>=1.5) at Visit 2.
* A best pre-bronchodilator morning (AM) FEV1 \>=30% and \<90% of the predicted normal value at Visit 2. Predicted values will be based upon the ERS Global Lung Function Initiative (Quanjer).
* Liver function tests at Visit 1:
1. Alanine aminotransferase (ALT) \<2 times upper limit of normal (ULN).
2. Alkaline phosphatase \<=1.5 times ULN.
3. Bilirubin \<=1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Compliance with completion of the Electronic diary reporting defined as completion of all questions/assessment on \>=4 of the last 7 days during the run-in period.
Exclusion Criteria
* Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
* Any asthma exacerbation requiring a change in maintenance asthma therapy in the 6 weeks prior to Visit 1.
* Participants with the diagnosis of chronic obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, including all of the following:
1. History of exposure to risk factors (especially tobacco smoke, occupational dusts and chemicals, smoke from home cooking and heating fuels).
2. A post-albuterol/salbutamol FEV1/Forced Vital Capacity (FVC) ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of less than or equal to (\<=)70% of predicted normal values.
3. Onset of disease \>=40 years of age.
* Participants with current evidence of pneumonia, active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases or abnormalities other than asthma.
* Immune suppression (e.g., Human Immunodeficiency virus \[HIV\], Lupus) or other risk factors for pneumonia (e.g., neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Participants at potentially high risk (e.g., very low Body Mass Index \[BMI\], severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator.
* Participants with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
* Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* Clinically significant Electrocardiogram (ECG) abnormality: Evidence of a clinically significant abnormality in the 12-lead ECG performed during screening. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the participant's medical history and exclude participants who would be at undue risk by participating in the trial. An abnormal and clinically significant finding is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following:
1. Atrial Fibrillation with rapid ventricular rate \>120 beats per minute (bpm).
2. Sustained or non-sustained ventricular tachycardia.
3. Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted).
4. QT interval corrected for heart rate by Fridericia's formula (QTcF) \>=500 milliseconds (msec) in participants with QRS \<120 msec and QTcF \>=530 msec in participants with QRS \>=120 msec.
* Participants with any of the following at Screening (Visit 1):
1. Myocardial infarction or unstable angina in the last 6 months.
2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months.
3. New York Heart Association (NYHA) Class IV Heart failure \[American Heart Association, 2016\].
* Participants with a medical condition such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy or bladder neck obstruction should only be included if in the opinion of the Investigator the benefit outweighs the risk and that the condition would not contraindicate study participation.
* Participants with carcinoma that has not been in complete remission for at least 5 years. Participants who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the participant has been considered cured by treatment.
* Participants with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
* Participants who are medically unable to withhold their albuterol/salbutamol for the 6-hour period required prior to spirometry testing at each study visit.
* Participants who are:
1. Current smokers (defined as participants who have used inhaled tobacco products within the 12 months prior to Visit 1, e.g. cigarettes, electronic-cigarettes/vaping, cigars or pipe tobacco).
2. Former smokers with a smoking history of \>=10 pack years (e.g. \>=20 cigarettes per day for 10 years).
* Participants with a known or suspected history of alcohol or drug abuse within the last 2 years.
* A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate.
* Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
* Study Investigators, sub-Investigators, study coordinators, employees of a participating Investigator or study site, or immediate family members of the aforementioned that is involved with this study.
* In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.
* Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the participant's asthma status or the participant's ability to participate in the study.
* Evidence of a severe exacerbation during screening or the run-in period, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
* Changes in asthma medication (excluding run-in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
* Evidence of clinically significant abnormal laboratory tests during screening or run-in which are still abnormal upon repeat analysis and are not believed to be due to disease(s) present. Each Investigator will use his/her own discretion in determining the clinical significance of the abnormality.
* Any asthma exacerbation requiring a change in maintenance asthma therapy in the 6 weeks prior to Visit 1.
* Participants with the diagnosis of chronic obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, including all of the following:
1. History of exposure to risk factors (especially tobacco smoke, occupational dusts and chemicals, smoke from home cooking and heating fuels).
2. A post-albuterol/salbutamol FEV1/Forced Vital Capacity (FVC) ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of less than or equal to (\<=)70% of predicted normal values.
3. Onset of disease \>=40 years of age.
* Participants with current evidence of pneumonia, active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases or abnormalities other than asthma.
* Immune suppression (e.g., Human Immunodeficiency virus \[HIV\], Lupus) or other risk factors for pneumonia (e.g., neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Participants at potentially high risk (e.g., very low Body Mass Index \[BMI\], severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator.
* Participants with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
* Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* Clinically significant Electrocardiogram (ECG) abnormality: Evidence of a clinically significant abnormality in the 12-lead ECG performed during screening. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the participant's medical history and exclude participants who would be at undue risk by participating in the trial. An abnormal and clinically significant finding is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following:
1. Atrial Fibrillation with rapid ventricular rate \>120 beats per minute (bpm).
2. Sustained or non-sustained ventricular tachycardia.
3. Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted).
4. QT interval corrected for heart rate by Fridericia's formula (QTcF) \>=500 milliseconds (msec) in participants with QRS \<120 msec and QTcF \>=530 msec in participants with QRS \>=120 msec.
* Participants with any of the following at Screening (Visit 1):
1. Myocardial infarction or unstable angina in the last 6 months.
2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months.
3. New York Heart Association (NYHA) Class IV Heart failure \[American Heart Association, 2016\].
* Participants with a medical condition such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy or bladder neck obstruction should only be included if in the opinion of the Investigator the benefit outweighs the risk and that the condition would not contraindicate study participation.
* Participants with carcinoma that has not been in complete remission for at least 5 years. Participants who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the participant has been considered cured by treatment.
* Participants with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
* Participants who are medically unable to withhold their albuterol/salbutamol for the 6-hour period required prior to spirometry testing at each study visit.
* Participants who are:
1. Current smokers (defined as participants who have used inhaled tobacco products within the 12 months prior to Visit 1, e.g. cigarettes, electronic-cigarettes/vaping, cigars or pipe tobacco).
2. Former smokers with a smoking history of \>=10 pack years (e.g. \>=20 cigarettes per day for 10 years).
* Participants with a known or suspected history of alcohol or drug abuse within the last 2 years.
* A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate.
* Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
* Study Investigators, sub-Investigators, study coordinators, employees of a participating Investigator or study site, or immediate family members of the aforementioned that is involved with this study.
* In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.
* Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the participant's asthma status or the participant's ability to participate in the study.
* Evidence of a severe exacerbation during screening or the run-in period, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
* Changes in asthma medication (excluding run-in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
* Evidence of clinically significant abnormal laboratory tests during screening or run-in which are still abnormal upon repeat analysis and are not believed to be due to disease(s) present. Each Investigator will use his/her own discretion in determining the clinical significance of the abnormality.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Beijing, , China
Site Status
GSK Investigational Site
Changchun, , China
Site Status
GSK Investigational Site
Changsha, , China
Site Status
GSK Investigational Site
Chengdu, , China
Site Status
GSK Investigational Site
Chongqing, , China
Site Status
GSK Investigational Site
Chongqing, , China
Site Status
GSK Investigational Site
Dongguan, , China
Site Status
GSK Investigational Site
Fuzhou, , China
Site Status
GSK Investigational Site
Guangzhou, , China
Site Status
GSK Investigational Site
Guangzhou, , China
Site Status
GSK Investigational Site
Guangzhou, , China
Site Status
GSK Investigational Site
Guangzhou, , China
Site Status
GSK Investigational Site
Guilin, , China
Site Status
GSK Investigational Site
Guilin, , China
Site Status
GSK Investigational Site
Hangzhou, , China
Site Status
GSK Investigational Site
Hangzhou, , China
Site Status
GSK Investigational Site
Hefei, , China
Site Status
GSK Investigational Site
Hohhot, , China
Site Status
GSK Investigational Site
Hohhot, , China
Site Status
GSK Investigational Site
Huizhou, , China
Site Status
GSK Investigational Site
Jiangmen, , China
Site Status
GSK Investigational Site
Jinan, , China
Site Status
GSK Investigational Site
Kunming, , China
Site Status
GSK Investigational Site
Lanzhou, , China
Site Status
GSK Investigational Site
Lianyungang, , China
Site Status
GSK Investigational Site
Nanchang, , China
Site Status
GSK Investigational Site
Nanjing, , China
Site Status
GSK Investigational Site
Nanning, , China
Site Status
GSK Investigational Site
Qingdao, , China
Site Status
GSK Investigational Site
Qingyuan, , China
Site Status
GSK Investigational Site
Qinhuangdao, , China
Site Status
GSK Investigational Site
Sanya, , China
Site Status
GSK Investigational Site
Sanya, , China
Site Status
GSK Investigational Site
Shanghai, , China
Site Status
GSK Investigational Site
Shanghai, , China
Site Status
GSK Investigational Site
Shanghai, , China
Site Status
GSK Investigational Site
Shanghai, , China
Site Status
GSK Investigational Site
Shanghai, , China
Site Status
GSK Investigational Site
Shenyang, , China
Site Status
GSK Investigational Site
Shenyang, , China
Site Status
GSK Investigational Site
Shenzhen, , China
Site Status
GSK Investigational Site
Shenzhen, , China
Site Status
GSK Investigational Site
Shenzhen, , China
Site Status
GSK Investigational Site
Shijiazhuang, , China
Site Status
GSK Investigational Site
Taiyuan, , China
Site Status
GSK Investigational Site
Tianjin, , China
Site Status
GSK Investigational Site
Ürümqi, , China
Site Status
GSK Investigational Site
Wenzhou, , China
Site Status
GSK Investigational Site
Wuhan, , China
Site Status
GSK Investigational Site
Wuhan, , China
Site Status
GSK Investigational Site
Wuxi, , China
Site Status
GSK Investigational Site
Xi'an, , China
Site Status
GSK Investigational Site
Xiamen, , China
Site Status
GSK Investigational Site
Xinxiang, , China
Site Status
GSK Investigational Site
Xuzhou, , China
Site Status
GSK Investigational Site
Yinchuan, , China
Site Status
GSK Investigational Site
Zhanjiang, , China
Site Status
GSK Investigational Site
Zhanjiang, , China
Site Status
GSK Investigational Site
Zhengzhou, , China
Site Status
GSK Investigational Site
Zhongshan, , China
Site Status
GSK Investigational Site
Zunyi, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
214263
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry
NCT01498653
COMPLETED
PHASE3
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.
NCT01498679
COMPLETED
PHASE3
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
NCT03363191
WITHDRAWN
PHASE4
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
NCT02446418
COMPLETED
PHASE3
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
NCT01147848
COMPLETED
PHASE3
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496
ACTIVE_NOT_RECRUITING
PHASE4
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
NCT01686633
COMPLETED
PHASE3
Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response
NCT01128569
COMPLETED
PHASE2
Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma
NCT07223294
NOT_YET_RECRUITING
PHASE3
To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)
NCT01725685
COMPLETED
PHASE1
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
NCT01165138
COMPLETED
PHASE3
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
NCT03879837
COMPLETED
PHASE3
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
NCT01436071
COMPLETED
PHASE3
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
NCT03184987
COMPLETED
PHASE3
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
NCT01687283
COMPLETED
PHASE3
Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma
NCT00830505
COMPLETED
PHASE4
A 12-Week Study in Adult Subjects With Asthma
NCT01516086
COMPLETED
PHASE2
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
NCT03207243
COMPLETED
PHASE2
Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents
NCT01159912
COMPLETED
PHASE3
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
NCT03273946
COMPLETED
Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma
NCT03012061
COMPLETED
PHASE2
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
NCT01134042
COMPLETED
PHASE3
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
NCT01453023
COMPLETED
PHASE2
12-Week Study in Adult Subjects With Asthma
NCT01516073
COMPLETED
PHASE2